Citius Pharmaceuticals, Inc. (CTXR)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 09-30. Amounts in USD.

Revenue Quarterly

0 1.5M 3M 4.5M Q1 '11: 0 Q2 '11: 0 Q3 '11: 0 Q4 '11: 0 Q1 '12: 0 Q2 '12: 0 Q3 '12: 0 Q4 '12: 0 Q1 '13: 0 Q2 '13: 0 Q3 '13: 0 Q4 '13: 0 Q1 '14: 0 Q2 '14: 0 Q3 '14: 0 Q4 '18: 0 Q4 '19: 0 Q4 '20: 0 Q4 '21: 0 Q4 '22: 0 Q1 '26: 3.9M Q2 '26: 1.7M Q3 '26: 1.5M Q2 '11 Q1 '12 Q4 '12 Q3 '13 Q2 '14 Q4 '19 Q4 '22 Q3 '26

Gross Profit Quarterly

0 1.5M 3M 4.5M Q1 '26: 3.2M Q2 '26: 1.3M Q3 '26: 1M Q1 '26 Q2 '26 Q3 '26

Operating Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q1 '17: -2.8M Q2 '17: -2.5M Q3 '17: -2.3M Q4 '17: -2.4M Q1 '18: -3.2M Q2 '18: -4.9M Q3 '18: -2M Q3 '18: -2M Q4 '18: -3.7M Q1 '19: -3.9M Q2 '19: -3.6M Q3 '19: -4.4M Q4 '19: -3.7M Q1 '20: -4.4M Q2 '20: -4.4M Q3 '20: -4.7M Q4 '20: -4.1M Q1 '21: -8.2M Q2 '21: -4.2M Q3 '21: -6M Q4 '21: -5.2M Q1 '22: -9.3M Q2 '22: -7.6M Q3 '22: -8.9M Q4 '22: -7.5M Q1 '23: -7.2M Q2 '23: -10.7M Q3 '23: -8.7M Q4 '23: -10.1M Q1 '24: -9.3M Q2 '24: -11M Q3 '24: -10.6M Q4 '24: -11.1M Q1 '25: -10M Q2 '25: -11.3M Q3 '25: -8.8M Q4 '25: -8.4M Q1 '26: -9M Q2 '26: -32.2M Q3 '26: -11.7M Q1 '18 Q1 '19 Q2 '20 Q3 '21 Q4 '22 Q1 '24 Q2 '25 Q3 '26

Net Income Quarterly

-30M -20M -10M 0 10M 20M 30M Q2 '17: -2.7M Q3 '17: -2.4M Q4 '17: -3M Q1 '18: -3.2M Q2 '18: -4.4M Q3 '18: -2M Q3 '18: -2M Q4 '18: -2.8M Q1 '19: -3.9M Q2 '19: -3.6M Q3 '19: -4.4M Q4 '19: -3.6M Q1 '20: -4.3M Q2 '20: -4.4M Q3 '20: -4.7M Q4 '20: -4.1M Q1 '21: -8.1M Q1 '21: -8.1M Q2 '21: -4.1M Q3 '21: -5.8M Q4 '21: -5M Q1 '22: -9.2M Q2 '22: -7.6M Q3 '22: -8.9M Q4 '22: -8M Q1 '23: -3.6M Q2 '23: -10.5M Q3 '23: -8.5M Q4 '23: -9.9M Q1 '24: 9.2M Q2 '24: -8.5M Q3 '24: -10.6M Q4 '24: -11.1M Q1 '25: -10.3M Q2 '25: -11.5M Q3 '25: -9.2M Q4 '25: -8.7M Q1 '26: -9.4M Q2 '26: -28.1M Q3 '26: -11.9M Q2 '18 Q2 '19 Q3 '20 Q3 '21 Q4 '22 Q1 '24 Q2 '25 Q3 '26

Cost of Revenue Quarterly

0 300K 600K 900K Q1 '26: 789.2K Q2 '26: 328.9K Q3 '26: 491.8K Q1 '26 Q2 '26 Q3 '26

Operating Cash Flow Quarterly

-15M -10M -5M 0 5M 10M 15M Q4 '16: -1.8M Q1 '17: -1.3M Q2 '17: -824.6K Q3 '17: -2.4M Q4 '17: -3.4M Q1 '18: -2.4M Q2 '18: -4.1M Q3 '18: -2.2M Q4 '18: -2.5M Q1 '19: -2.2M Q2 '19: -3.8M Q3 '19: -3.5M Q4 '19: -2.9M Q1 '20: -5.1M Q2 '20: -4.5M Q3 '20: -4M Q4 '20: -3.4M Q1 '21: -9.6M Q2 '21: -4.3M Q3 '21: -4.8M Q4 '21: -5.6M Q1 '22: -4.7M Q2 '22: -9.7M Q3 '22: -7.7M Q4 '22: -6.3M Q1 '23: -4.8M Q2 '23: -7.9M Q3 '23: -9.6M Q4 '23: -6.8M Q1 '24: -6.1M Q2 '24: -7.8M Q3 '24: -8.4M Q4 '24: -5.9M Q1 '25: -4.7M Q2 '25: -4.5M Q3 '25: -5.4M Q4 '25: -11.9M Q1 '26: -13M Q2 '26: -1.3M Q3 '26: -8.7M Q4 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '22 Q1 '24 Q2 '25 Q3 '26

Free Cash Flow Quarterly

-6M -4M -2M 0 2M 4M 6M Q4 '20: -3.4M Q4 '21: -5.6M Q4 '20 Q4 '21

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 60M 120M 180M Q1 '11: 18M Q2 '11: 18M Q3 '11: 18M Q1 '12: 18M Q2 '12: 18M Q3 '12: 18M Q1 '13: 18M Q2 '13: 18M Q3 '13: 18M Q1 '14: 18M Q2 '14: 18M Q3 '14: 18M Q2 '21: 96M Q3 '21: 137.2M Q1 '22: 146M Q2 '22: 146M Q3 '22: 146.1M Q1 '23: 146.2M Q2 '23: 146.3M Q3 '23: 153.8M Q1 '24: 6.4M Q2 '24: 6.4M Q3 '24: 7M Q1 '25: 7.5M Q2 '25: 8.6M Q3 '25: 11M Q1 '26: 21.5M Q2 '26: 22.4M Q3 '26: 26.2M Q1 '11 Q2 '12 Q3 '13 Q2 '21 Q3 '22 Q1 '24 Q2 '25 Q3 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-10.50 -7.00 -3.50 0.00 3.50 7.00 10.50 Q2 '16: -1.40 Q3 '16: -2.12 Q4 '16: -1.32 Q1 '17: -1.72 Q2 '17: -2.25 Q3 '17: -1.98 Q4 '17: -1.89 Q1 '18: -1.83 Q2 '18: -1.72 Q3 '18: -1.43 Q2 '19: -0.79 Q3 '19: -0.80 Q4 '19: -0.78 Q1 '20: -0.71 Q2 '20: -0.64 Q3 '20: -0.55 Q4 '20: -0.46 Q1 '21: -0.46 Q2 '21: -0.37 Q3 '21: -0.31 Q4 '21: -0.27 Q1 '22: -0.18 Q2 '22: -0.19 Q3 '22: -0.20 Q4 '22: -0.22 Q1 '23: -0.18 Q2 '23: -0.20 Q3 '23: -0.20 Q4 '23: -5.57 Q1 '24: -7.00 Q2 '24: -8.27 Q3 '24: -9.78 Q4 '24: -5.96 Q1 '25: -5.81 Q2 '25: -5.74 Q3 '25: -4.97 Q4 '25: -3.48 Q1 '26: -2.56 Q2 '26: -2.24 Q3 '26: -1.78 Q2 '17 Q3 '18 Q2 '20 Q3 '21 Q4 '22 Q1 '24 Q2 '25 Q3 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.